The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout attributable to GI events, and management evidence.
I have vomited three times in the last ten days, always in the twenty-four to forty-eight hours after my injection, always in the morning, and each time I felt…
Every summary I read says nausea is "the most common adverse event" and then quotes a single percentage, usually without saying which trial, which dose or which…
The nausea followed exactly the pattern I was told to expect: bad for a fortnight after each dose step, better by week four, essentially gone by month five. The…
Eight weeks in on tirzepatide and I cannot work out which of two things is happening, and I think it matters. Version A: my appetite drive is genuinely reduced, food…
Fourteen weeks in, currently at the second-to-top dose, and I have been told repeatedly that the nausea settles. It has not settled. It has changed shape. Weeks 1-6…
I have had slow bowels since starting semaglutide and I have accepted that as the trade. Last week was different and it frightened me: four days with nothing, a hard…
Concretely: reflux · nine · cagrilintide. I have read the obvious sources and they disagree with each other, so I would rather ask people who have actually done this.…
The specifics, since they change the answer: early satiety · eight · semaglutide. Everything I have found on this is either a forum aside or a product page, neither…
This came up because two published schedules for the same agent differ. I would like to know the limits of what can be inferred from this. What I am trying to avoid…
The case in front of me: reflux · orforglipron. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know…
What I am working with: 2.4 mg · two weeks · early satiety. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me…
Stated plainly: early satiety · tirzepatide · SURPASS-2. I have read the primary source rather than the summary, which has left me with more questions. I understand…
What I have: 15 mg · sixteen weeks · reflux. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how…
The case in front of me: early satiety · two · survodutide. This is a procedural question rather than a theoretical one, and I would like the procedure rather than…
What I have: SURMOUNT-4 · early satiety. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
I am trying to calibrate how likely it is that GI side effects end up being the reason someone stops, as opposed to being an unpleasant thing they get through. The…
The specifics, since they change the answer: STEP 5 · early satiety. I have the document in front of me and I can read the numbers. What I cannot do is interpret…
The particulars: reflux · seven · a GLP-1 receptor agonist. I want a method I can write down and repeat, not a rule of thumb. I would rather over-engineer this than…
Conditions: reflux · dulaglutide. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I would still…
Details up front: ATTAIN-1 · early satiety · 12 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…
For the avoidance of doubt, nothing here is urgent — I would be in a clinic rather than a text box. This is one of those things that everyone repeats and nobody…
Setup, so nobody has to ask: SUSTAIN-6 · reflux · 2 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand…
Stated plainly: SURMOUNT-2 · reflux. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
Setup, so nobody has to ask: early satiety · a GLP-1 receptor agonist. The empirical answer seems settled. The explanation does not. If the honest answer is that…
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse results